AI주식인사이트AI Stock Insight
B

아이진

185490KOSDAQ

63.8 / 100

Reference Date: 2026-09-09

Financial Score19.5 / 40
News Sentiment21.3 / 25
Momentum13.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Surged 20.6% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Ajin is a biotech venture company focused on R&D in medicine and pharmacy, specializing in the development of next-generation innovative therapies such as mRNA-based vaccines and AAV gene therapies. The company is also advancing revenue-generating projects, including meningococcal vaccines and botulinum toxin development, while investing in promising ventures to secure key technologies.

Number of Employees

49people

Average Salary

58.6M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 15.004.0Point
PBR
1.61Industry Average 1.202.5Point

Higher than industry avg (caution)

ROE
-36.31Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
7.00Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20255.0 / 10 points
Revenue Growth Rate
2.0 / 3

Avg ▲6.8% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲38.4% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -30.8% (declining, 3yr)

Detailed News Sentiment

8 totalPositive 8Neutral 0Negative 0Average Sentiment Score 85

Detailed Momentum

52-week position6.0Point

52w upper range (60%)

Current 2,020Won52-week high 2,55652-week low 1,193
1-month return6.0Point

1m +20.60% (strong rise)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0
  • Neutral반기보고서 (2026.06)2026-08-14